

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/008826

International filing date: 16 March 2005 (16.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 10/801,982
Filing date: 16 March 2004 (16.03.2004)

Date of receipt at the International Bureau: 20 April 2005 (20.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1307732

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 12, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 10/801,982

FILING DATE: *March 16, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/08826*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



16367 U.S. PTO

031604

PTO/SB/05 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	AMBI:094US
First Inventor	Marianna Goldrick
Title	Process and Reagents for Extraction of RNA from Fractionated Blood Leukocytes
Express Mail Label No.	EV 323284105 US

22390

107801982



031604

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 38]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 8]
5. Oath or Declaration [Total Sheets]
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ Paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Prior application information:

Examiner

Art Unit:

For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number: 32425 OR ☐ Correspondence address below

Name

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print/Type)

Mark B. Johnson

Registration No. (Attorney/Agent)

37,259

Signature

Date

03/16/2004

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT

ATTY DKT: AMBI:094US

APPLICATION FOR UNITED STATES LETTERS PATENT
FOR
PROCESS AND REAGENTS FOR EXTRACTION OF RNA FROM
FRACTIONATED BLOOD LEUKOCYTES

by
Marianna Goldrick

EXPRESS MAIL MAILING LABEL

NUMBER EV 323284105 US

DATE OF DEPOSIT March 16, 2004

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to processes for fractionating white blood cells (also called
5 “WBCs” or “leukocytes”) from blood, for extending the half-life of RNA molecules
thereby stabilizing the RNA in the fractionated cells, and for extracting RNA from the
fractionated cells. The invention further relates to the analysis of mRNA, including
mRNA expression patterns, using techniques such as expression profiling and RT-PCR.
The invention further relates to analysis of small RNAs including micro-RNAs
10 (“miRNAs”), siRNAs, etc.

2. Description of Related Art

Blood is the most accessible human tissue from which appreciable amounts of
RNA can be recovered. It is also the most expendable, since a substantial amount can be
removed with no ill effects and it is rapidly regenerated. Blood also has a unique ability
15 to report events that are widely disseminated, since the design of the circulatory system
ensures that blood cells are in intimate contact with tissues in essentially all parts of the
body. This means that circulating leukocytes have the potential to act as sentinel cells for
the surveillance of distant tissues affected by infection, cancer, inflammation, and genetic
and metabolic diseases (Whitney *et al.*, 2002; Alcorta *et al.*, 2002). For example a recent
20 report describes changes in mRNA patterns in density gradient-fractionated lymphocytes
that correlate with central nervous system pathologies including ischemic stroke and
seizure in a rat model system (Tang *et al.*, 2001).

The promise of high-density microarrays to identify global changes in mRNA
expression that correlate with diagnosis, prognosis, and treatment outcome is now being
25 realized. Expression profiling assays have identified differences in mRNA patterns that
are associated with inflammatory and metastatic disease, exposure to toxic and infectious
agents, and ionizing radiation. Once microarray analysis has identified the key mRNA
changes, simpler, cheaper, and more sensitive assays, such as quantitative RT-PCR, may
be developed for clinical purposes. To facilitate both the discovery phase and the clinical

implementation of mRNA expression profiling, methods are needed for rapidly stabilizing the RNA in clinical samples, especially in human blood.

However, as discussed below, there are several technical challenges to using blood as source tissue for mRNA expression profiling.

5 **Challenges in the Isolation of RNA from Blood**

One initial challenge is that the concentration of actively metabolizing cells (*i.e.*, cells that contain mRNA) in blood is low. The concentration of mRNA in blood is therefore relatively low. Less than 50% of blood by weight and volume is comprised of cells (>50% of blood is non-cellular plasma), and of the cellular fraction, only ~ 0.1-0.2%
10 is comprised of leukocytes, the remainder being mostly mature red blood cells (“RBCs” or “erythrocytes”), which do not generally express mRNA. The vast majority (>99%) are mature red cells, which contain no appreciable mRNA but have high concentrations of heme. Heme is a potent inhibitor of enzymatic reactions including reverse transcription and PCR. Since virtually all protocols for extraction of cellular RNA require disruption
15 of the tissue in several volumes of extraction reagent (typically ~ 3 - 10 volumes), the use of unfractionated whole blood as source tissue results in a further dilution of the sample and complicates RNA recovery. For example, processing of 10 ml of whole blood using conventional procedures (Choczymski/Sacchi, Trizol) would require the addition of 100 ml (10 volumes) of lysis solution. The resulting sample volume is impractical for use in
20 organic extraction and solid-phase extraction protocols.

Another challenge is that blood contains high concentrations of intracellular and extracellular ribonucleases (Moenner *et al.*, 1997) making recovery of intact mRNA difficult.

An important complication of expression profiling in whole blood is the presence
25 of high numbers (relative to number of leukocytes) of immature RBC (“reticulocytes”), which contain high levels of mRNA for α and β globin. When RNA is extracted from whole blood and amplified for use in microarray expression profiling assays, the product of globin mRNA predominates in the amplified material and results in dramatically reduced sensitivity (Affymetrix Technical Notes, “Blood RNA Isolation Methods for
30 GeneChip Expression Analysis”; “An Analysis of Blood Processing Methods to Prepare

Samples for GeneChip Expression Profiling”). This globin mRNA contamination compromises the use of the RNA as input for microarray profiling.

Methods for Fractionating WBCs from Whole Blood

For practical reasons, as set forth above, whole blood is often fractionated to
5 concentrate the nucleated cells (*i.e.*, the WBCs) prior to RNA extraction or immunoselection. Removing plasma and red cells eliminates many of the nucleases and inhibitors from blood and reduces the sample volume by at least ten-fold, which allows RNA extraction to be carried out in microfuge tubes (<2 ml) instead of larger vessels. Also, most protocols for immunoselection of leukocyte subsets are more efficient and
10 cost-effective when carried out on fractionated leukocytes rather than whole blood.

Density gradient centrifugation is probably the most common method for fractionating whole blood; a blood sample (several milliliters) is diluted and then layered onto a viscous polysaccharide polymer (sold commercially as Ficoll-Hypaque) and centrifuged for ~ 30 minutes under conditions that cause the red blood cells and
15 granulocytes to sediment below the polymer, while the lymphocytes (B-cells and T-cells) and other mononuclear cells (including monocytes and leukemic blasts) form a band within the polymer (Theophilus, 1998). The band is withdrawn by aspiration and the sample is diluted to allow the lymphocytes to be re-pelleted, then the cells are washed in PBS, collected again by centrifugation, and then either used directly for RNA isolation or
20 expanded by tissue culture prior to RNA extraction. Although high-quality RNA can generally be recovered from blood cells processed in this way, the procedure is time-consuming and labor-intensive, and the extensive manipulation required may result in significant changes in mRNA profiles prior to RNA extraction and analysis. There has been only one study to date that described changes in mRNA expression between whole
25 blood and lymphocytes fractionated via density gradient (Hartel *et al.*, 2001). That group found increases in several cytokine mRNAs (IL-4, IL-2, TNF-alpha) in Ficoll-fractionated lymphocytes.

A variation on Ficoll separation is a commercially available device (“CPT tubes”, BD) that allows the blood to be drawn directly into the tube containing the polymer gel.
30 After centrifugation, the plasma and lymphocytes are decanted, residual cells are washed

from the sides of the tube, the cells are diluted and re-pelleted, and then usually put into tissue culture prior to RNA isolation. No reagent is included in the CPT tube to stabilize the expression profile during these manipulations.

Another method for fractionating leukocytes for subsequent RNA extraction is to
5 selectively lyse the RBCs in several volumes of ammonium chloride solution or other
RBC lysis reagent and recover the leukocytes by centrifugation (Duvigneau *et al.*, 2003).
This procedure requires inconvenient increases in sample volume and subjects the sample
to highly unphysiological conditions that may alter the expression profile, and results in a
low yield and quality of RNA recovered. Another method for fractionating leukocytes is
10 to centrifuge the anticoagulated whole blood at low speed ($\sim 2,000 \times g$) for ~ 15 minutes
to separate the “buffy coat” (*i.e.*, the WBCs) at the interface between the plasma and the
packed red cells. The buffy coat can be collected by aspiration after removing the
plasma. An advantage of this method is that the leukocytes are fractionated under
conditions that are arguably closer to physiological conditions than the methods
15 described above. However, collection of buffy coat is still a time-consuming process that
requires centrifugation and other manipulations that may alter mRNA expression
patterns. Also, it is messy and labor-intensive and carries a risk of exposing healthcare
workers to blood-borne pathogens. Further, the buffy coat fraction containing leukocytes
is highly contaminated with RBCs and reticulocytes, and thus also contaminated with
20 globin mRNA.

Pall Corporation manufactures leukocyte depletion matrices that are used in blood
transfusion therapy to deplete donor immune cells and thus reduce problems of graft-vs-
host disease in recipients. Two reports in the literature describe retrieval of leukocyte
depletion filter-captured leukocytes from blood bank by-products (Weitkamp and Crowe,
25 2001; Ebner *et al.*, 2001). Subsets of cells (dendritic cells or B-cells) were then selected
using density gradient fractionation and antibody-coated magnetic beads, and the cells
recovered were used to establish viable cell lines. However, such filters have evidently
not been used in the context of recovery of RNA from primary WBCs.

Methods for Extracting RNA from Whole Blood

Most methods for extracting RNA from whole blood or fractionated leukocytes involve an initial lysis of the sample in guanidinium thiocyanate. For example, one such method involves solid-phase extraction onto a silica matrix wherein a blood sample is lysed in a guanidinium solution, and the cell lysate is mixed with ethanol and applied to the silica filter, which binds RNA. Other methods are based on lysis of whole blood in cationic detergents (Macfarlane and Dahle, 1997) or in lithium chloride/urea solutions. Commercial products for isolating RNA from blood include the Ambion RiboPure-Blood kit (Ambion) and the PAXgene system (PreAnalytix). A limitation of all of the above methods for isolating RNA from blood is that all the cells, including RBCs and reticulocytes, are lysed in the first step. This can result in contamination of the leukocyte RNA with globin mRNAs and precludes subsequent fractionation of leukocyte subsets. A method of reducing such contamination would be beneficial.

RNA Requirements for Expression Profiling

The requirements for RNA for use in microarray analysis and RT-PCR are somewhat different than those for historically used RNA analysis methods such as Northern blots and nuclease protection assays. The most significant difference is that rather than relying only on the ability of the sample RNA to hybridize to a probe, the current methods require that the RNA serve as an efficient substrate for reverse transcription. Reverse transcription converts the sample RNA into cDNA in order to incorporate fluorescent labels or other detectable moieties (for microarray analysis), or to generate a cDNA template for subsequent amplification by thermostable DNA polymerase (for RT-PCR). An important requirement for the sample RNA is that it must not contain contaminants that would inhibit enzymatic reactions. In the case of RNA extraction from blood, it is important that the RNA be free from contamination with heme, a well-known inhibitor of reverse transcription and DNA polymerase. In terms of amounts of RNA required for expression studies, microarray analysis has historically required relatively large amounts, ranging from $\sim 2 - 20 \mu\text{g}$. However, an emerging trend is to use much smaller amounts of total RNA. This is made possible by using linear amplification strategies to enzymatically increase the amount of input RNA, and/or by

using more sensitive detection methods that result in signal amplification. These technical advances have made it possible to carry out microarray experiments using only a few cells (Xiang *et al.*, 2003). These considerations suggest that microarray analysis on uncultured primary leukocyte subclasses will be feasible.

5 **Expression Profiling of Blood**

It has been proposed that determining characteristic patterns of gene expression in circulating peripheral blood cells may prove broadly useful for noninvasive diagnostics (Staudt and Brown, 2000). Most microarray experiments that have been carried out using blood as the sample have used density-gradient-fractionated peripheral blood mononuclear cells (PBMCs), which are often expanded in tissue culture prior to RNA
10 extraction. Fractionation of PBMCs *via* density gradient centrifugation is, however, a labor-intensive and time-consuming process that carries a high risk of exposing workers to blood-borne pathogens (since it is carried out in open vessels) and permits only several milliliters of blood to be used per preparation. An even more serious drawback to density
15 gradient fractionation and culturing the recovered cells is that the manipulations required may result in changes in the endogenous mRNA levels, which will compromise interpretation of mRNA expression profiling assays. Another drawback is that density gradient fractionation fails to recover a major subset of mature WBCs (those of the myeloid lineage) from whole blood.

20 In order to discover mRNA patterns in circulating WBCs that correlate with diagnosis, prognosis, and treatment outcome, it is important to freeze the mRNA pattern in the cells prior to RNA extraction, so that it accurately reflects the relative levels of endogenous gene expression. Numerous reports document changes in mRNA levels in unstabilized blood samples, as described below.

25 Any changes in mRNA levels in blood cells that occur during sample collection and handling will interfere with the quantitative detection of specific mRNA changes for diagnostic purposes. There are many reports in the literature of changes in mRNAs in untreated *ex vivo* blood. For example, adherence of monocytes to the plastic walls of tubes used for blood collection causes induction of mRNAs for proinflammatory

cytokines (Haskill *et al.*, 1988). Significant increases were reported in mRNA expression of several cytokines including IL-2, IL-4, and tumor necrosis factor alpha, that were associated with Ficoll density gradient separation and with other blood collection parameters (Hartel *et al.*, 2001). Lag times of greater than one hour between sample collection and processing were reported to cause alterations in some but not all cytokines tested in a porcine blood system (Duvigneau *et al.*, 2003). Increases in levels of several cytokine mRNAs in human whole blood after *ex vivo* storage were also reported (Pahl and Brune, 2002). Based on real-time RT-PCR assays, Stordeur *et al.* (2002) demonstrated that interferon γ mRNA is rapidly degraded in *ex vivo* blood with a half-life of about one hour. Probably the most extensive study dealing with mRNA changes in untreated whole blood during *ex vivo* storage is a recent report by Rainen *et al.* (2002). This group compared levels of 25 mRNAs (including cytokines, transcription factors, apoptosis-related genes, tumor suppressor genes, *etc.*) in RNA isolated from whole blood from a single donor stored for increasing times at room temperature in either standard EDTA-anticoagulated vacutainer tubes or in the cationic detergent solution used in the PAXgene blood RNA isolation system (described above). The mRNA levels were determined by qRT-PCR and expressed relative to that of 18S ribosomal RNA. The mRNA levels from RNA isolated using the two methods at each *ex vivo* time point (4 hours, 8 hours, 24 hours, 3 days, and 5 days) were then compared to the levels seen in RNA isolated from EDTA blood samples immediately after blood collection. The extent of mRNA changes was greater for the EDTA blood compared to the blood stabilized in the PAXgene system, although changes were observed for both conditions. Interestingly, the relative levels of some mRNAs (*e.g.*, interleukin 8, c-jun oncogene) were observed to increase over time in the EDTA tubes, while others (*e.g.*, caspase 1, heat shock protein 70) were seen to decrease. Overall, increases in relative mRNA levels were as likely to occur as decreases over time in EDTA anticoagulated blood, and increases were more often observed than decreases for the PAXgene system.

All of the above reports exemplify that gene-specific changes in mRNA levels occur in unstabilized *ex vivo* blood over relatively short time scales. Such changes will compromise the discovery of mRNA expression patterns associated with disease and prognosis.

For the above reasons, and others, there is a need for methods for immediately fractionating the WBC population from whole blood, and for stabilizing the mRNA expression profile in the fractionated leukocytes, in order to facilitate extraction of mRNA from blood for use in clinical assays.

5

SUMMARY OF THE INVENTION

The current invention relates generally to methods for rapid fractionation of WBCs from whole blood using a proprietary leukocyte depletion filter, and for subsequent stabilization of the RNA patterns in the fractionated cells. The invention
10 further relates to methods of extracting the RNA, and in some cases DNA, from the fractionated cells and using such nucleic acids in any of a variety of molecular biology procedures including, for example, expression profiling and RT-PCR.

Some preferred embodiments of the invention involve methods of obtaining a leukocyte lysate comprising RNA comprising fractionating leukocytes from whole blood
15 using a leukocyte depletion matrix and lysing the fractionated leukocytes to obtain a lysate comprising RNA. In some embodiments the leukocytes are comprised on the matrix at the time they are lysed, i.e., there is no steps of eluting or removing the leukocytes from the matrix prior to lysing are needed. However, there are certainly embodiments of the invention in which it is possible to remove the leukocytes prior to
20 processing.

In some embodiments, the leukocyte comprising matrix is stored for a period of time prior to lysis of the leukocytes. For example, this storage may be minutes, hours, days, weeks, or years. In some embodiments of the invention, treatment of the leukocyte comprising matrix with an RNA preservation solution prior to storage is employed.

25 Lysis of the fractionated leukocytes is often accomplished with a lysis solution, although other methods of lysis known to those of skill may be employed. Such lysis solutions often contain a detergent, for example, Triton X-100, Tween-20, SDS (sodium dodecyl sulfate), sarcosyl, deoxycholic acid, etc. The lysis solution may also contain a chaotropic agent, for example, a guanidinium salt such as guanidinium thiocyanate. The

lysis solution may also comprise a ribonuclease inhibitor, such as those described in: (i) U.S. provisional application entitled "Nuclease Inhibitors for Use In Biological Applications" by Latham *et al.*, filed on February 25, 2004; and (ii) U.S. non-provisional application entitled "Improved Nuclease Inhibitor Cocktail" by Latham *et al.*, filed on
5 February 25, 2004, which is a continuation-in-part application of co-pending U.S. Application No. 10,675,860 filed September 30, 2003, which is a continuation of Application No. 09/669,301 filed September 25, 2000, now U.S. Patent 6,664,379, which claims the benefit of U.S. Provisional Application No. 60/155,874, filed September 24, 1999. The entire text of each of the foregoing applications and patents is specifically
10 incorporated herein by reference without disclaimer.

Some preferred embodiments comprise extracting the RNA from the lysate. In many cases, this extraction is performed via an organic extraction. In some preferred embodiments, the organic extraction is a phenol/chloroform extraction. These methods may also comprise isolating DNA from the lysate. Of course, in the context of isolating
15 DNA from the lysate, either in combination with RNA or alone, those of skill will typically not wish to employ the procedures taught herein for reducing DNA contamination in those protocols where only RNA isolation is desired. Preferred embodiments comprise, prior to lysis, treating the fractionated leukocytes with an RNA preservation composition comprising a salt that infiltrates the leukocytes and increases
20 the half-life of the RNA compared to the RNA in cells not treated with the preservation composition. Such an RNA preservation medium is the Ambion product RNAlater®, which is covered by U.S. Patents No. 6,204,375 and 6,528,641, the entire contents of which are incorporated herein by reference. In some preferred methods, the salt is a sulfate salt, for example but not limited to ammonium sulfate. In some embodiments, the
25 final salt concentration in the preservation composition is between 10 g/100 ml and a saturating concentration; between 20 g/100 ml and the saturating concentration of the salt; and/or between 30 g/100 ml and 80 g/100 ml. The RNA preservation composition may comprises at least two, three, four, or more salts. In some preferred embodiments, the fractionated leukocytes are comprised on the leukocyte depletion matrix and the
30 matrix is contacted with the RNA preservation composition. These embodiments may then involve extracting RNA from the fractionated leukocytes with an organic extraction.

An advantage in this regard is that the extracted RNA has less DNA contamination than would RNA extracted from fractionated leukocytes that were not treated with the RNA preservation medium. For example, it is possible to obtain 95%, 90%, 85%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, and/or 25% or more less DNA contamination in this manner, including but not limited to a range of percentage reduction between any of these specific points.

In some specific embodiments, the invention involves: fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix; lysing the fractionated leukocytes to produce a lysate; extracting the lysate with an organic solution to form organic and aqueous phases; separating the organic and aqueous phases after the organic phase has been absorbed into the matrix; and isolating RNA from the aqueous phase.

In other more specific embodiments, some methods of the invention comprise: fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix; treating the fractionated leukocytes with an RNA preservation composition comprising a salt that infiltrates the leukocytes, increasing the half-life of the RNA; lysing the fractionated leukocytes to produce a lysate; extracting the lysate with an organic solution to form organic and aqueous phases; separating the organic and aqueous phases; and isolating RNA from the aqueous phase.

Other embodiments comprise: fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix; treating the fractionated leukocytes with an RNA preservation composition comprising a salt that infiltrates the leukocytes, increasing the half-life of the RNA; lysing the fractionated leukocytes to produce a lysate; and isolating RNA from the lysate.

Further embodiments are defined as comprising: fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix; lysing the fractionated leukocytes to produce a lysate; and isolating RNA from the lysate.

Some embodiments of the invention comprise assaying for the presence or quantity of one or more RNAs in the lysate. Such assaying may comprise any form of molecular biological assay suitable for assaying RNA, whether known at the time of the

filing of this specification or developed later. Those of skill, in view of this specification will understand how to adapt the invention to such assays. Such assays may be used in the context of research and/or diagnostic protocols. Such assaying may comprise a Northern blot, RNase protection assay, hybridization reaction, microarray analysis, or reverse transcriptase-polymerase chain reaction analysis. Embodiments comprising the use of reverse transcriptase-polymerase chain reaction, may be further defined as employing real-time RT-PCR or endpoint RT-PCR.

RNA obtained from lysates may also be assayed in protocols that comprise a microarray analysis. In some preferred embodiments, the microarray analysis may comprise the use of a cDNA array, spotted oligonucleotide array, or in-situ synthesized oligonucleotide array. As discussed herein, a benefit of some embodiments of the invention is that it allows for a reduction in the amount of α globin and β globin gene mRNA contamination from reticulocytes, greatly facilitating WBC RNA analysis, such as microarray analysis.

In some embodiments, the invention relates to a kit for extracting total RNA from leukocytes comprising: a leukocyte depletion matrix; and a cell lysis solution as described above. In some embodiments, the leukocyte depletion matrix is comprised in a carrier adapted to allow blood to be passed through the matrix during use. Such a carrier can be adapted to be fitted to a syringe. The kits of some embodiments are adapted to function in a manner that allows whole blood to be moved from a closed container through the matrix and then, as leukocyte-depleted blood, into a further closed container. One or more containers may be included in the kit. The kits may also include other components including but not limited to one, two, or three of: an RNA preservation composition comprising a salt that infiltrates leukocytes and increases the half-life of the RNA in the leukocytes; an organic extraction reagent; and/or a solid-phase extraction matrix and reagents for washing the matrix to remove impurities before elution of the RNA.

The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."

It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and *vice versa*. Furthermore, compositions of the invention can be used to achieve methods of the invention.

5 Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

 The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although
10 the disclosure supports a definition that refers to only alternatives and “and/or.”

 As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and
15 “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments
20 of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

25 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1 Efficiency on capture of leukocytes on Pall LK4 leukocyte depletion matrix.

FIG. 2 High-quality RNA recovered from LK4-fractionated leukocytes.

FIG. 3A and FIG. 3B High-quality RNA is shown by analysis on Agilent 2100
5 Bioanalyzer.

FIG. 4 RNA is more stable in LK4-fractionated leukocytes which are subsequently treated with *RNAlater* compared to RNA in untreated LK4-fractionated leukocytes.

FIG. 5 *RNAlater* treatment reduces genomic DNA contamination.

10 **FIG. 6A, FIG. 6B, FIG. 6C, FIG. 6D, FIG. 6E, and FIG. 6F** LK4-fractionation of blood reduces globin RNA contamination.

DETAILED DESCRIPTION OF THE INVENTION

The inventors have devised new methods for fractionating leukocytes and
15 extracting mRNA from them. These methods involve the use of a leukocyte depletion filter, such as that produced by Pall Corporation, to capture leukocytes, followed by isolation of RNA from the captured leukocytes. The inventors have, in one embodiment, shown that a Pall leukocyte depletion filter, for example their filter designated "LK4," enables one to recover WBCs from whole blood for subsequent RNA extraction.
20 Volumes of whole blood as large as 20 ml can be rapidly filtered (in approximately one minute) at the point of collection using a manual syringe format, which makes the method amenable to RNA extraction in the field. No centrifugation or mixing with other solutions is required. Further, the inventors have developed a closed-tube format for WBC fractionation, which offers minimal risk of exposure to blood-borne pathogens.
25 WBC filtration is expected to perturb the mRNA profile of isolated leukocytes less than any of the alternative leukocyte fractionation methods, since it can be completed within 1 to 2 minutes of blood collection and does not subject the cells to the effects of centrifugal force. The yield and quality of RNA recovered using this method are excellent.

RNA*later* is a reagent developed at Ambion, which stabilizes RNA in tissue samples. RNA*later*, and various embodiments of it, are described in U.S. Patents No. 6,204,375 and 6,528,641, both entitled "Methods and Reagents for Preserving RNA in Cell and Tissue Samples," the full disclosures of which are incorporated herein in their entirety. One aspect of the present invention is a procedure for rapid fractionation of WBCs from whole blood and for rapid stabilization of mRNA in the fractionated cells using RNA*later*.

Methods of Isolation of WBCs from Blood

There are a variety of manners in which to isolate WBCs from whole blood, many of which have been discussed above. However, in the context of the present invention, a preferred method of isolation involves the use of a filter medium enabling RBCs, blood plasma, and other non-WBC blood components to pass through while trapping WBCs. Any form of filter medium that will accomplish this purpose is expected to be useful in the context of the invention. Further, by following the teachings of this specification, those of skill will be able to test any potential filters for suitability in the methods of the invention, by employing the potential filters in assay procedures such as taught in the Examples and analyzing the results.

Presently preferred filters for WBC isolation are the leukocyte depletion matrices sold by Pall Corporation, under the name Leukosorb[®] Medium. Leukosorb is a fibrous medium that was originally designed for the depletion of WBCs from blood for transfusion.. Descriptions of the Leukosorb products and their use may be found in U.S. Patent Nos.: 5,501,795, 5,100,564, 4,880,548, 4,923,620, 4,925,572, 5,229,012, and 5,344,561, as well as U.S. Patent Application No. 20030134417, the entire contents of which are each incorporated herein by reference. In the studies discussed below, the LK4 Leukosorb filters were used.

Methods of Isolating RNA from WBCs

There are many method for isolating RNA from cells, known to those of skill in the art and most or all of them are adaptable to the present invention.

Most methods for extracting total RNA from whole blood and fractionated leukocytes involve an initial lysis of the sample in guanidinium thiocyanate, a potent

chaotrope that disrupts cell membranes and denatures proteins, including nucleases. One commonly used commercial reagent, TRIzol® (Life Technologies, Inc.), consists of a mixture of guanidinium salts and phenol. In a standard protocol, whole blood is mixed with three volumes of TRIzol reagent, then chloroform is added and the prep is centrifuged to separate it into organic and aqueous phases. The RNA is precipitated out of the aqueous phase with isopropanol and the pellet washed with ethanol to reduce contaminants.

Another common method for purifying RNA from blood involves solid-phase extraction onto a silica matrix. The blood sample is lysed in a guanidinium solution or other lysis solution, and the cell lysate is mixed with ethanol and applied to the silica filter, which binds RNA. The filter is washed to remove contaminants and the RNA is then eluted with water. A DNase digestion step is typically recommended in all RNA isolation methods to eliminate contaminating genomic DNA.

Other methods are based on lysis of whole blood in cationic detergents (Macfarlane and Dahle, 1997) or in lithium chloride/urea solutions.

Commercial products for isolating RNA from blood include the Ambion RiboPure-Blood kit (Ambion) and the PAXgene® system (PreAnalytix). The use of the RiboPure-Blood kit is described in the Examples below. In the PAXgene system, blood samples of ~ 2.5 ml are drawn directly into evacuated blood collection tubes containing ~7.5 ml of lysis solution. After storage of the sample at room temperature for at least 2 hours, the RNA is pelleted, washed, treated with protease, then the prep is mixed with ethanol and then purified over a silica filter as described above.

Methods of Using RNA and DNA Isolated from WBCs

RNA and DNA isolated from WBCs in the manner of the invention may be used in any molecular biological technique involving RNA or DNA, as will be understood by those of skill in the art.

Some preferred embodiments of the invention involve expression profiling for research and/or diagnostic purposes, as described below. Other embodiments involve the use of RNA isolated from WBCs in reverse transcriptase-polymerase chain reaction

protocols, such as those described in U.S. Patent Publication No. 20030170617, entitled
“Crude biological derivatives competent for nucleic acid detection,” by Pasloske, the
entire disclosure of which is incorporated herein by reference. In one preferred
embodiment of the invention, WBCs isolated using the leukocyte depletion filters
described herein are treated with the methods described in U.S. Patent Publication No.
20030170617.

Other uses include analysis of levels of expression of mRNAs transcribed from
one or several genes, analysis of global mRNA expression levels, analysis of expression
levels of small endogenous and exogenous RNA molecules such as micro RNAs and
small interfering RNAs, and discovery of and analysis of genetic polymorphisms
including mutations and SNPs.

For example, assays such as Northern blots, RNase protection assays, S1 nuclease
protection assays, and reverse transcription polymerase chain reaction (RT-PCR) may be
used in analysis of levels of one or a few mRNAs. A particularly useful assay for one or
several mRNA species is a modification of RT-PCR known as real-time RT-PCR (also
known as quantitative RT-PCR). In general, these assays are either based on
hybridization of an RNA sample to a labeled probe, for example to an RNA or DNA
probe labeled by incorporation of a nucleotide coupled to a detectable moiety such as 32-
P or biotin or digoxigenin; or the assays are based on conversion of target RNAs in the
RNA sample to complementary DNA (cDNA) using retroviral reverse transcriptase
enzyme(s), for example reverse transcriptase isolated from or derived from Moloney
Murine Leukemia Virus (M-MuLV) or from Avian Myeloblastosis Virus (AMV) or from
human immunodeficiency virus (HIV), with subsequent amplification of the cDNA
target(s) using PCR or using RNA polymerase enzymes such as T7, T3, and Sp6 RNA
polymerases.

Methods of Expression Profiling

RNA recovered from fractionated blood cells using the present invention can be
used as input for expression profiling experiments that aim to discover patterns of mRNA
levels that correlate with disease, prognosis, and response to treatment.

In general, RNA used for expression profiling is converted to complementary DNA (cDNA) by enzymes having reverse transcriptase activity, and detectable moieties, for example fluorescently labeled dNTPs or biotinylated dNTPs, are incorporated into the cDNA during the reverse transcription step. The labeled cDNA is then hybridized to
5 elements arrayed on a solid support, such that a detectable signal, for example fluorescence, is associated with elements that are specific for distinct mRNAs. The elements on the array can consist of oligonucleotides or cDNAs complementary to target mRNAs.

Requirements for input RNA are that it not contain inhibitors of reverse
10 transcriptase or levels of genomic DNA which could interfere with specific detection of the desired mRNA targets.

Another undesirable contaminant in input RNA used for expression profiling from leukocytes is mRNA from the α - and β -globin genes. A complication of expression profiling using input RNA extracted from unfractionated whole blood is the presence of
15 high numbers (relative to number of leukocytes) of immature red blood cells, known as reticulocytes, which contain high levels of mRNA for α - and β -globin. When RNA is extracted from whole blood and amplified for use in microarray expression profiling assays, the product of globin mRNA predominates in the amplified material and results in dramatically reduced sensitivity for detection of other mRNAs of interest. (Affymetrix
20 Technical Notes, "Blood RNA Isolation Methods for GeneChip Expression Analysis"; "An Analysis of Blood Processing Methods to Prepare Samples for GeneChip Expression Profiling"). This globin mRNA contamination compromises use of the RNA as input for microarray profiling. A particular advantage of the current invention is that most reticulocytes are removed during the process of fractionating the blood over the leukocyte
25 depletion filter.

EXAMPLES

The following examples are included to further illustrate various aspects of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques and/or compositions discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1

Efficiency of Capture of Leukocytes on Leukocyte Depletion Matrix

A study was carried out to demonstrate the efficiency with which leukocytes are captured from whole blood using a prototype device. Six 10 ml samples of EDTA blood were passed through Pall Corporation LK4 filters and the filtrates were collected in fresh tubes. The filtrates were then centrifuged for 15 minutes at 3,200 rpm in a swinging bucket centrifuge in order to recover any WBCs that were not captured as a buffy coat fraction. Buffy coats were collected using disposable wide-bore transfer pipettes.

RNA was extracted from LK4 filters and from the corresponding buffy coat fractions using the Ambion RiboPure-Blood kit. Briefly, this protocol involves lysing the WBCs (which may be captured onto the leukocyte depletion matrix or which may be present in whole blood or in the buffy coat fraction of blood) in a guanidinium thiocyanate-based lysis solution, adding sodium acetate to reduce the pH of the preparation, adding low-pH phenol/chloroform and vortexing the preparation thoroughly and then storing it for 5 minutes at room temperature. The mixture is then centrifuged to separate the aqueous and organic phases, and the upper aqueous phase is removed to a new vessel and mixed with an appropriate volume of absolute ethanol, for example with one-half volume of absolute ethanol. The lower, organic phase, which contains most of the contaminating heme and plasma and cellular proteins, is discarded. The aqueous phase + ethanol mixture is then filtered through a silica membrane, where RNA binds to

the silica matrix. The silica matrix is washed with a first wash solution, containing guanidinium and other proprietary components, followed by washing with a second wash solution containing ethanol and other proprietary components. The filtration and wash steps are accomplished by passing the solutions through the silica filter by centrifugation or by vacuum filtration. After the wash steps are completed, the silica filter is centrifuged to remove residual fluid and the filter is transferred to a second vessel, for example a 2 ml microfuge tube. The RNA is then eluted from the silica filter by applying preheated nuclease-free water containing 0.1 mM EDTA to the silica matrix and centrifuging the assembly to recover the RNA.

The RNA from each sample was eluted in 200 μ l, and 15 μ l of each prep was analyzed on a denaturing agarose gel in the presence of ethidium bromide, as shown in FIG. 1. Samples were loaded in pairs, with the LK4-recovered RNA in the first lane and the corresponding filtrate-recovered RNA loaded in the adjacent lane. The efficiency of WBC capture from whole blood using the filter matrix in this format ranged from ~ 75 – 85%, as shown in FIG. 1. This efficiency is more than adequate to obtain sufficient RNA for use as input in microarray expression profiling experiments.

Example 2

High-quality RNA Can be Recovered from Filter Matrix-Fractionated Leukocytes

FIG. 2, FIG. 3A and FIG. 3B show the yield and quality of RNA recovered from LK4-fractionated cells using the methods of the present invention.

FIG. 2 shows analysis of the RNA via agarose gel electrophoresis. Anticoagulated blood (10 ml) was filtered through 2.5 cm-diameter circles of LK4 using one of two formats. In this study, the samples in the first 3 lanes were processed using a format in which the LK4 filter remains in the disposable syringe device and the extraction reagents are flushed through the filter to release the RNA. The sample in the last lane in FIG. 2 was recovered from blood processed using LK4 in a reusable syringe device format in which the filter was removed from the device for processing. The RNA from each sample was eluted in 200 μ l of nuclease-free water containing 0.1 mM EDTA, and

15 μ l of each prep was analyzed on a denaturing 1% agarose gel in the presence of ethidium bromide. Intact high-quality RNA is apparent as evidenced by the sharp bands of ethidium-staining material corresponding to the signature 18S (lower band) and 28S (upper band) ribosomal RNA. The RNA recovered using the format in which the LK4
5 filter is removed (lane 4 in FIG. 2) consistently showed a higher level of contamination with genomic DNA, compared to the alternative format, in which the filter is processed *in situ* (lanes 1-3 in FIG. 2). The purity of RNA recovered from the LK4-captured cells was also assessed by determining the UV- absorbance values at 260 nm and 280 nm; the 260:280 ratios spanned a narrow range from 1.9 – 2.1, indicative of highly pure RNA.

10 FIG. 3A and FIG. 3B show RNA analyzed *via* microfluidic separation on an Agilent 2100 Bioanalyzer. Analysis of RNA on the Agilent Bioanalyzer, for example, is particularly useful in regard to some embodiments of the invention, as this instrument provides a numerical value for the ratio of peak heights of the 18S and 28S rRNAs. The ~5 kilobase 28S rRNA is more susceptible to degradation than the ~ 2 kb 18S rRNA, and
15 so higher 28S:18S rRNA values are associated with RNA which is more highly intact. Although a consensus 28S:18S rRNA value indicative of RNA of sufficient quality to use as input for microarray experiments is still emerging, it has been suggested that RNA should have a 28S:18S rRNA ratio of at least 1 to be used most successfully for this application. FIG. 3A and FIG. 3B show representative Agilent Bioanalyzer data for two
20 RNA preps extracted from LK4-fractionated leukocytes using the format in which the filter is removed from the device for processing. These preps were treated with DNase 1 after elution. One microliter of each prep was mixed with a sample-loading solution containing a proprietary dye that binds specifically (or at least, preferentially) to RNA and was run on the Agilent chip. The 28S:18S rRNA peak height ratios are all well
25 above the cut-off value of 1. In general, the yield of RNA from this type of prep, as determined by the Agilent software, ranges from ~ 30 to 60 ug per 10 ml of blood.

Example 3

***RNAlater* Treatment Preserves RNA in Fractionated WBCs**

The data shown in Figure 4 demonstrate the benefit of treating LK4-captured cells with *RNAlater* for preserving RNA intactness, as shown by more intensely-staining 18S and 28S ribosomal RNA bands in samples treated with *RNAlater*, compared to untreated samples. A particular advantage of treating LK4-captured cells with *RNAlater* is that said treatment allows the device containing the captured cells to be transported at ambient temperature from the point of sample collection to a distant-site lab for RNA extraction and analysis. Transporting samples at ambient temperature reduces the costs associated with RNA analysis.

To obtain these data, duplicate 10 ml EDTA blood samples from 3 healthy donors were filtered over LK4 leukocyte depletion matrix contained in disposable syringe filter units. One of each pair of samples was filtered over a disposable filter unit device having a design called “ring-molded”, and the other was filtered through a disposable filter unit having an alternative design called “psf”. After filtering the blood, the captured cells on some filters were treated with *RNAlater* by passing 2 ml of *RNAlater* through the LK4 matrix; the *RNAlater* was delivered via a 3 ml syringe attached to the filter unit containing the LK4 matrix with captured cells.

The filter units containing the LK4 captured cells were removed from the syringes and shipped via overnight courier at ambient temperature from the sample collection point to the laboratory. RNA was extracted from the LK4-captured cells, eluted in 230 uL of water containing 0.1 mM EDTA, and 15 ul (~ 6.5% of each prep) was mixed with 8 uL of denaturing gel-loading solution containing 10 ug/ml ethidium bromide and resolved by electrophoresis on a denaturing agarose gel. The samples in each lane were as follows: Lane 1-Donor #1, sample filtered through ring-molded device, treated with *RNAlater*; Lane 2-Donor #1, sample filtered through psf device, treated with *RNAlater*; Lane 3-Donor #2, sample filtered through ring-molded device, treated with *RNAlater*; Lane 4-Donor #2, sample filtered through psf device, treated with *RNAlater*; Lane 5-Donor #3, sample filtered through ring-molded device, NOT treated with *RNAlater*;

Lane 6-Donor #3, sample filtered through psf device, NOT treated with *RNAlater*; and Lane 7-reference RNA sample, not processed at same time as other samples.

As can be seen in the data in FIG. 4, those samples not treated with *RNAlater* had significantly degraded RNA, as opposed to those treated with *RNAlater*. These data show that *RNAlater* treatment results in significant advantages in the context of the invention.

Example 4

***RNAlater* Treatment Reduces Genomic DNA Contamination**

FIG. 5 shows the advantage of exposing the filtered leukocytes to *RNAlater* to reduce genomic DNA contamination. All samples were from 10 ml of EDTA-blood filtered through a 2.5 cm-diameter LK4 filter and stored for 4 days in a room temperature as indicated. Approximately 7% of the RNA recovered from each prep was analyzed on a denaturing agarose gel. In lane 1, the filter was not treated. In lane 2, the filter was stored in 2.4 ml of guanidinium thiocyanate lysis solution. In lane 3, the filter was treated with 3 ml of *RNAlater* before storage. Lane 4 shows a positive control RNA with the filter not treated, not stored, and treated with DNase post-elution. Note that there was severe degradation of RNA in the filter stored for 4 days at room temperature in GuSCN solution (Lane 2). Further, note that DNA contamination was greatly reduced in the sample (in Lane 3) treated with *RNAlater* prior to extraction.

Example 5

Filter Matrix Fractionization of WBCs Reduces Globin mRNA Contamination

A study was carried out to assess the extent to which LK4 fractionation reduces the undesired product of contaminating globin mRNAs in the amplified RNA (aRNA), compared to the amount of globin mRNA-derived amplified RNA from whole blood or from WBCs fractionated by centrifugation.

Several tubes of EDTA anticoagulated blood from a single donor were processed. Total RNA was extracted from LK4 fractionated WBCs, from whole blood, and from WBCs fractionated by centrifugation (“buffy coat” fractionated WBCs). The RNA from these three types of samples was used as input for linear amplification mediated by T7 RNA polymerase, using the Ambion MessageAmp™ kit. Non-blood-derived RNA from the kit (from the human HeLa cell line) was included as positive control. After first-strand and second-strand synthesis, the double-stranded cDNA was transcribed with T7 RNA polymerase and the aRNA (amplified RNA) reaction products were mixed with a proprietary RNA-binding fluorescent dye matrix and analyzed on the Agilent 2100 Bioanalyzer. This instrument separates heterogeneous RNA molecules according to size, with smaller molecules migrating faster than larger molecules.

FIG. 6A, FIG. 6B, FIG. 6C, FIG. 6D, FIG. 6E, and FIG. 6F show data from this study. In each of these, the horizontal axis indicates time and the vertical axis indicates fluorescent intensity. The arrows in each panel indicate the “spike” of amplified RNA derived from α and β globin mRNAs (as described in the Affymetrix Technical Bulletin, “Globin Reduction Protocol: A Method for Processing Whole Blood RNA Samples for Improved Array Results”). The samples from the positive control HeLa RNA are not expected to have globin aRNA spikes, since these were not amplified from blood-derived RNA. The magnitude of the globin aRNA spike in FIG. 6A and FIG. 6B, which contain RNA amplified from LK4-fractionated WBCs, is significantly reduced compared to the magnitude of the globin aRNA spike in FIG. 6C and FIG. 6D, which contain aRNA from unfractionated whole blood. The globin aRNA spike is also dramatically lower in the LK4-fractionated samples compared to the globin aRNA spike in the buffy-coat fractionated sample in FIG. 6E. FIG. 6F contains aRNA from the HeLa cell line control RNA, and hence does not show any spike of globin product.

Example 6

Exemplary Procedure for Isolating mRNA from Leukocytes

In a preferred method of the invention, a leukocyte depletion filter, for example an LK4 filter, is cut or provided which fits a syringe filter unit that allows the filter to be

recovered after filtering the blood. This method has can be used to filter 40 ml or more of blood without filter clogging.

Exemplary steps are as follows:

1. Obtain a sample, for example 10 to 20 ml, of anticoagulated whole blood
5 using any manner known, for example, using EDTA as an anticoagulant and collecting the blood in a standard evacuated tube, i.e. a Vacutainer tube.
2. Transfer the blood to a syringe, for example as 20 – 30 ml syringe or other appropriate receptacle. In some embodiments, this is done without opening the tube of blood, by using a vented spike inserted through the stopper of the blood collection tube
10 and attached via a luer fitting to the syringe.
3. Attach a filter device containing a leukocyte depletion filter, for example a ~ 2.5 cm diameter circle of filter, to the syringe and pass the blood through the filter. The inventors typically pass the blood through the filter at a rate such that it drips at ~ 2 - 4 drops per second. The leukocyte-depleted blood can be collected in a waste container for
15 disposal, or it can be collected and retained for use in other clinical assays. After all blood has passed through, pump ~ 10 ml of air through the filter to flush out most of the residual blood (this will often come out as foamy material). This step fractionates the leukocytes onto the filter and concentrates the sample ~ 50-fold. An alternative configuration for carrying out this step is to place the leukocyte depletion filter device
20 between the vented spike inserted into the blood collection tube and the syringe used to draw the blood through the filter. In this case, the leukocytes will be collected on the distal face of the filter (with respect to the syringe), and the leukocyte-depleted blood will be transferred to the syringe and can then be disposed of.
4. Treat the leukocyte depletion filter containing the captured leukocytes
25 with *RNAlater*. One way to do this is to attach a syringe containing *RNAlater* to the filter device containing the filter and flush the *RNAlater* through the filter. Typically 2 - 3 ml of *RNAlater* is sufficient. All fluid can be flushed, but the passing of too much air through the filter should be avoided, to prevent drying the filter. The filter should remain damp with *RNAlater*. An alternative way to do this is to insert the vented spike

described above into a container with *RNAlater* and aspirate the *RNAlater* up through the filter into the syringe.

5. Open the device that houses the filter and remove the filter with forceps; place it into, for example, a 15 ml polypropylene disposable conical centrifuge tube (15 ml Falcon tube). The filter with *RNAlater*-stabilized leukocytes may be stored at ambient temperature for at least one week before RNA isolation.

6. To extract the RNA, use the reagents from the Ambion RiboPure-Blood™ kit, or any other appropriate RNA extraction procedure. If using the Ambion RiboPure-Blood kit, the steps of isolation are roughly as follows. Obviously, the steps, amounts, and concentrations in these procedures are subject to modification or substitution by those of skill in the art.

a. Add 2.4 ml of guanidinium thiocyanate lysis solution and 0.15 ml of sodium acetate solution to the 15 ml tube with the filter and shake for 30 seconds.

b. Add 1.5 ml of acid-phenol/chloroform to the tube and shake for 30 seconds, then store the prep for 5 minutes at room temperature.

c. Centrifuge the prep for 10 minutes at 3,200 rpm in a table-top centrifuge.

d. Aspirate or pour off the aqueous phase into a second 15 ml tube and add one-half volume of ethanol and vortex to mix; volume of prep at this stage is ~ 4.5 ml.

e. Pass the prep over a silica filter in a microcentrifuge cartridge format (RNAqueous filter cartridge); this will require ~ 6 passes of spinning for ~ 10 seconds each, if using a centrifuge, but can be done more easily using a vacuum manifold or syringe format.

f. Wash the filter with 0.7 ml of Wash Solution #1.

g. Wash the filter twice with 0.7 ml each time of Wash Solution #2/3, then centrifuge the filter for 1 minute to dry it.

h. Elute the RNA from the filter with ~200 µl of Elution Solution preheated to ~ 75 °C.

7. If desired, treat the RNA with DNase 1 to eliminate residual genomic DNA; inactivate the DNase with DNA-free resin (recommended method).

5

Example 7

Exemplary Closed System for Rapid Fractionation of WBCs

The present invention allows for a closed system for rapid fractionation of WBCs from whole blood.

For example, one can filter leukocytes from anticoagulated whole blood collected
10 in standard evacuated tubes (Vacutainer® tubes, BectonDickinson). In this regard, the rubber closure of the tube is pierced by a vented transfer spike, which is attached via a luer fitting to the inlet port of a syringe filter device containing a 2.5 cm diameter circle of leukocyte depletion matrix.

A standard 10 ml disposable syringe is attached to the outlet port of the filter
15 device, and the blood is drawn through the filter into the syringe. The filtrate does not show any hemolysis and can be retained for blood chemistry tests or other assays. Other configurations can also be used for filtering the blood, for example the blood can be poured into the syringe (after removing the plunger and attaching the leukocyte depletion matrix containing device) and filtered by positive pressure. Transfer of a 10 ml blood
20 sample through a 2.5 cm LK4 filter typically takes less than one minute.

Advantages of this method are that it is rapid, eliminates exposure to blood-borne pathogens, and does not require any equipment such as centrifuges. This latter consideration means that the method is amenable to use in field situations where electrical power is unavailable, and in situations where centrifugation is impractical, such
25 as in B3 biohazard containment hoods with limited space for bulky equipment. It will be appreciated by those of skill in the art that alternative formats can also be used to pass whole blood through filters in closed systems or even in open systems, for example

where the blood collection tube is opened and the blood is poured into a syringe barrel with a filter device attached.

In some embodiments of the invention, the filter media remains within a housing throughout the WBC fractionation and RNA extraction process. This format provides
5 benefits of ease and contamination prevention in some applications. However, in other embodiments, the filter media may be removed from a housing after fractionation but before RNA extraction.

All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the methods of
10 this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and/or in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that
15 certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

References

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- Alcorta D, Preston G, Munger W, Sullivan P, Yang YY, Waga I, Jennette JC, and Falk R. Microarray studies of gene expression in circulating leukocytes in kidney disease. *Exp Nephrol* 10:139-149 (2002).
- Alizadeh AA, (28 additional authors), Brown PO, and Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 403:503-511 (2000).
- Chomczynski P and Sacchi N. Single-step method of RNA isolation by acid guanidinium phenol chloroform extraction. *Anal. Biochemistry* 162:156-159 (1987).
- Claes K, Poppe B, Machackova E, Coene I, Foretova L, De Paepe A, and Messiaen L. Differentiating pathogenic mutations from polymorphic alterations in the splice sites for BRCA1 and BRCA2. *Genes Chromosomes Cancer* 37:314-320 (2003).
- Cummings CA and Relman DA. Using DNA microarrays to study host-microbe interactions. *Emerg Infect Disease* 6:513-525 (2000).
- Duvigneau JC, Hartl RT, Teinfalt M, and Gemeiner M. Delay in processing porcine whole blood affects cytokine expression. *J Immunological Methods* 272:11-21 (2003).
- Ebner S, Neyer S, Hofer S, Nussbaumer W, Romani N, and Heufler C. Generation of large numbers of human dendritic cells from whole blood passaged through leukocyte removal filters: an alternative to standard buffy coats. *J. Immunol Methods* 252:93-104 (2001).
- Grace MB, McLeland CB, and Blakely WF. Real-time quantitative RT-PCR assay of GADD45 gene expression changes as a biomarker for radiation biodosimetry. *Int'l Journal of Radiation Biology*, 78:1011-21 (2002).
- Guhaniyogi J and Brewer G. Regulation of mRNA stability in mammalian cells. *Gene* 265:11-23 (2001).

- Hartel C, Bein G, Muller-Steinhardt M, and Kluter H. Ex vivo induction of cytokine mRNA expression in human blood samples. *J Immunological Methods* 249:63-71 (2001).
- Haskill S, Johnson C, Eierman D, Becker S, and Warren K. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. *J Immuno* 140:1690-1694 (1988).
- Hodge DL, Schill WB, Wang JM, Blanca I, Reynolds DA, Ortaldo JR, and Young HA. IL-2 and IL-12 alter NK cell responsiveness to IFN-gamma-inducible protein 10 by down-regulating CXCR3 expression. *J Immunol* 168:6090-6098 (2002).
- Kaufman SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. *Cancer Res* 51:1129-1136 (1991).
- Macfarlane DE and Dahle CE. Isolating RNA from clinical samples with Catrimox-14 and lithium chloride. *J Clin Lab Anal* 11:132-139 (1997).
- Magalhaes MC, Serra TA, and Magalhaes MM. RNA synthesis inhibitors on young rat adrenal in primary culture. An ultrastructural study. *Tissue Cell* 19:167-175 (1987).
- Moenner M, Hatzi E, and Badet J. Secretion of ribonucleases by normal and immortalized cells grown in serum-free culture conditions. *In vitro Cell Cev Biol Anim* 33:553 (1997).
- Pahl A and Brune K. Stabilization of gene expression profiles in blood after phlebotomy. *Clinical Chemistry* 48:2251-2253 (2002).
- Raghavan A, Ogilvie RL, Reilly C, Abelson ML, Raghavan S, Vasdewan J, Krathwohl M, and Bohjanen PR. Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes. *Nucleic Acid Res* 30:5529-5538 (2002).
- Rainen L, Oelmueller U, Jurgensen S, Wyrich R, Ballas C, Schram J, Herdman C, Bankaitis-Davis D, Nicholls N, Trollinger D, and Tryon V. Stabilization of mRNA expression in whole blood samples. *Clinical Chemistry* 48:1883-1890 (2002).

- Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu H-C, Mahfouz R, Raimondi SC, Lenny N, Patel A, and Downing, JR. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. *Blood* 102:2951-2959 (2002).
- Scheuermann RH and Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. *Leuk Lymphoma* 18:385 – 397. (1995).
- Stahlberg A, Aman P, Ridell B, Mostad P, and Kubista M. Quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression. *Clinical Chemistry* 49:51-59 (2003).
- Staudt LM and Brown PO. Genomic views of the immune system. *Annual Review Immunology* 18:829-859 (2000).
- Stordeur P, Zhou L, and Goldman M. Analysis of spontaneous mRNA cytokine production in peripheral blood. *J Immunol Methods* 261:195-197 (2002).
- Tang Y, Aigang L., Aronow BJ, and Sharp FR. Blood Genomic Responses Differ After Stroke, Seizures, Hypoglycemia, and Hypoxia: Blood genomic fingerprints of disease. *Ann Neurol* 50:699-707 (2001).
- Theophilus, BDM, RNA Isolation and characterization protocols, pp 39-41, edit. R. Rapley and DL Manning, Humana Press, Totowa NJ, 1998
- Verdeil G, Puthier D, Nguyen C, Schmitt-Verhulst AM, and Auphan-Anezin N. Gene profiling approach to establish the molecular basis for partial versus full activation of naïve CD8 T lymphocytes. *Ann NY Acad Sci* 975:68-76 (2002).
- Weitkamp JH and Crowe JE. Blood Donor Leukocyte Reduction Filters as a Source of Human B Lymphocytes. *BioTechniques* 31:464-466 (2001).
- Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, and Brown PO. Individuality and variation in gene expression patterns in human blood. *PNAS* 100:1896-1901 (2003).
- Xiang CC, Chen M, Kozhich OA, Phan QN, Inman JM, Chen Y, and Brownstein MJ. Probe generation directly from small numbers of cells for DNA microarray studies. *BioTechniques* 34:386-393 (2003).

- Yeoh, E-J, Ross, ME, Shurtleff, SA, Williams, WK, Patel, D., Mahfouz, R, (14 other co-authors), and Downing, JR. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell* March 2002, pp 133 – 143.
- Zhu H, Cong JP, Mamtora G, Gingeras T, and Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. *PNAS* 95:14470-14475 (1998).

WHAT IS CLAIMED IS:

1. A method of obtaining a leukocyte lysate comprising RNA comprising fractionating leukocytes from whole blood using a leukocyte depletion matrix and lysing the fractionated leukocytes to obtain a lysate comprising RNA.
2. The method of claim 1, wherein the leukocytes are comprised on the matrix at the time they are lysed.
3. The method of claim 2, wherein the leukocyte comprising matrix is stored for a period of time prior to lysis of the leukocytes.
4. The method of claim 1, wherein the fractionated leukocytes are contacted with a lysis solution.
5. The method of claim 4, wherein the lysis solution comprises a detergent.
6. The method of claim 5, wherein the detergent is Triton X-100, Tween-20, SDS (sodium dodecyl sulfate), sarcosyl, or deoxycholic acid.
7. The method of claim 4, wherein the lysis solution contains a chaotropic agent.
8. The method of claim 7, wherein the chaotropic agent is a guanidinium salt.
9. The method of claim 8, wherein the guanidinium salt is guanidinium thiocyanate.
10. The method of claim 4, wherein the lysis solution comprises a ribonuclease inhibitor.
11. The method of claim 1, further comprising extracting the RNA from the lysate.

12. The method of claim 11, wherein extracting the RNA is performed via an organic extraction.
13. The method of claim 12, wherein the organic extraction is a phenol/chloroform extraction.
14. The method of claim 11, further comprising extracting RNA and DNA from the lysate.
15. The method of claim 1, comprising, prior to lysis, treating the fractionated leukocytes with an RNA preservation composition comprising a salt that infiltrates the leukocytes and increases the half-life of the RNA compared to the RNA in cells not treated with the preservation composition.
16. The method of claim 15, wherein the salt is a sulfate salt.
17. The method of claim 16, wherein the salt is ammonium sulfate.
18. The method of claim 15, wherein the final salt concentration in the preservation composition is between 10 g/100 ml and a saturating concentration.
19. The method of claim 17, wherein the salt is present in the preservation composition at a final concentration of between 20 g/100 ml and the saturating concentration of the salt.
20. The method of claim 17, wherein the salt is present in the preservation composition at a final concentration of between 30 g/100 ml and 80 g/100 ml.
21. The method of claim 15, wherein the RNA preservation composition comprises at least two salts.

22. The method of claim 21, wherein the total salt concentration is present in the preservation composition at a final concentration of between 20 g/100 ml and 100 g/100 ml.

23. The method of claim 15, wherein the fractionated leukocytes are comprised on the leukocyte depletion matrix and the matrix is contacted with the RNA preservation composition.

24. The method of claim 15, further comprising extracting RNA from the fractionated leukocytes with an organic extraction.

25. The method of claim 24, wherein the extracted RNA has less DNA contamination than would RNA extracted from fractionated leukocytes that were not treated with the RNA preservation medium.

26. The method of claim 1, further defined as comprising:
fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix;
lysing the fractionated leukocytes to produce a lysate;
extracting the lysate with an organic solution to form organic and aqueous phases;
separating the organic and aqueous phases; and
isolating RNA from the aqueous phase.

27. The method of claim 1, further defined as comprising:
fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix;
treating the fractionated leukocytes with an RNA preservation composition comprising a salt that infiltrates the leukocytes, increasing the half-life of the RNA;
lysing the fractionated leukocytes to produce a lysate;
extracting the lysate with an organic solution to form organic and aqueous phases;

separating the organic and aqueous phases; and
isolating RNA from the aqueous phase.

28. The method of claim 1, further defined as comprising:
fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix;
treating the fractionated leukocytes with an RNA preservation composition comprising a salt that infiltrates the leukocytes, increasing the half-life of the RNA;
lysing the fractionated leukocytes to produce a lysate; and
isolating RNA from the lysate.
29. The method of claim 1, further defined as comprising:
fractionating leukocytes from blood by capturing them with a leukocyte depletion matrix;
lysing the fractionated leukocytes to produce a lysate; and
isolating RNA from the lysate.
30. The method of claim 1, further comprising assaying for the presence or quantity of one or more RNAs in the lysate.
31. The method of claim 30, wherein assaying comprises a Northern blot, RNase protection assay, hybridization reaction, microarray analysis, or reverse transcriptase-polymerase chain reaction analysis.
32. The method of claim 31, wherein assaying comprises a reverse transcriptase-polymerase chain reaction further defined as real-time RT-PCR or endpoint RT-PCR.
33. The method of claim 31, wherein assaying comprises a microarray analysis.

34. The method of claim 34, where the microarray analysis comprises the use of a cDNA array, spotted oligonucleotide array, or *in-situ* synthesized oligonucleotide array.
35. A kit for extracting total RNA from leukocytes comprising:
a leukocyte depletion matrix; and
a cell lysis solution.
36. The kit of claim 35, wherein the leukocyte depletion matrix is comprised in a carrier adapted to allow blood to be passed through the matrix during use.
37. The kit of claim 36, wherein the carrier is adapted to be fitted to a syringe.
38. The kit of claim 35, further defined as adapted to function in a manner that allows whole blood to be moved from a closed container through the matrix and then, as leukocyte-depleted blood, into a further closed container.
39. The kit of claim 35, further comprising an RNA preservation composition comprising a salt that infiltrates leukocytes and increases the half-life of the RNA in the leukocytes.
40. The kit of claim 35, further comprising an organic extraction reagent.
41. The kit of claim 40, further comprising a solid-phase extraction matrix and reagents for washing the matrix to remove impurities before elution of the RNA.

ABSTRACT

The current invention relates generally to methods for rapid fractionation of WBCs from whole blood using a proprietary leukocyte depletion filter, which concentrates and partially purifies the WBCs, and for stabilizing the RNA patterns in the
5 fractionated cells. The invention further relates to methods of extracting the RNA from the fractionated cells and using such nucleic acids in any of a variety of molecular biology procedures including, for example, expression profiling.

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4

1 2 3 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F